Flamel, Laboratoires Servier S.A., Novo Nordisk deal

NVO will terminate in March its development deal for FLML's Basulin long-acting insulin product (see BioCentury, Dec. 13, 1999). Basulin, which is in Phase I testing, uses FLML's Medusa nanoencapsulation technology to provide once-daily dosing, and FLML said it will reacquire rights to license the Medusa delivery technology for use with insulin. FLML said it will continue to develop the product and will seek another development and marketing partner. ...